Acalabrutinib clinical trials
Also written ACP-196 and Calquence.
Includes 1 study of Acalabrutinib maleate anhydrous.
How each study uses acalabrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the acalabrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 31 Oct 2017 · CALQUENCE · NDA 210259 (FDA, Drugs@FDA)
- European Union
- 5 Nov 2020 · Calquence · EMEA/H/C/005299 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
122 studies that test it; most in 2021 (22); 1 more planned to start later
| Year | Studies |
|---|---|
| 2014 | 7 |
| 2015 | 12 |
| 2016 | 7 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 12 |
| 2020 | 21 |
| 2021 | 22 |
| 2022 | 6 |
| 2023 | 9 |
| 2024 | 6 |
| 2025 | 6 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 52 · Other 71
Acerta Pharma BV (33) · AstraZeneca (16) · M.D. Anderson Cancer Center (9) · City of Hope Medical Center (5) · Fred Hutchinson Cancer Center (2) · Mayo Clinic (2) · Washington University School of Medicine (2) · University of Washington (2)
Often tested with
Tested in the same studies.
Obinutuzumab (16) · Venetoclax (15) · Rituximab (14) · Tafasitamab (5) · Lenalidomide (4) · Bendamustine (3) · Ibrutinib (3) · Durvalumab (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 4 phase 3 studies under way
Acalabrutinib is the comparator. A study of two new drugs counts under both.
- 1Pirtobrutinib · Loxo Oncology, Inc. · next primary completion Nov 2027
- 1ARQ531 · Merck Sharp & Dohme LLC · next primary completion Sep 2032
- 1Sonrotoclax · BeOne Medicines · next primary completion Feb 2031
- 1Zanubrutinib · BeOne Medicines · next primary completion Feb 2031
- 1Rocbrutinib · Guangzhou Lupeng Pharmaceutical Company LTD. · next primary completion May 2031
Reaching primary completion within a year · 26, 5 in phase 3
Studies that test acalabrutinib, phase 3 first.
- Feb 2027A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLPhase 3 · Acerta Pharma BV
- Feb 2027A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Phase 3 · Acerta Pharma BV
- Apr 2027Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPhase 3 · Acerta Pharma BV
- Jul 2027A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPhase 3 · AstraZeneca
- Aug 2027A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.Phase 3 · Ascentage Pharma Group Inc.
- Dec 2026ACALA-R In Predominantly Demyelinating IgM Mediated NeuropathyPhase 2 · Shayna Sarosiek, MD
- Dec 2026Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaPhase 1 · University of Alabama at Birmingham
- Dec 2026Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System LymphomaPhase 1 · Washington University School of Medicine
- Dec 2026A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaPhase 2 · ECOG-ACRIN Cancer Research Group
- Dec 2026Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 2 · Seema Bhat
Studies
Open first, then newest update. How each study uses acalabrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 123
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04002947Written as Acalabrutinib
- MACE and BTK InhibitorsNot yet recruitingPhase 4University Hospital, CaenNCT07923162Written as Acalabrutinib
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingPhase 2City of Hope Medical CenterNCT07582159Written as Acalabrutinib
- Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 2City of Hope Medical CenterNCT06054776Written as Acalabrutinib
- Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialNot yet recruitingPhase 2University of WashingtonNCT07910435Written as Acalabrutinib
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT04404088Written as Acalabrutinib
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingPhase 2AstraZenecaNCT05952024Written as Acalabrutinib
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 2Mayo ClinicNCT03516617Written as Acalabrutinib
- Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialRecruitingPhase 2Fred Hutchinson Cancer CenterNCT04941716Written as Acalabrutinib
- MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingPhase 2AstraZenecaNCT07024706Written as Acalabrutinib
- Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureRecruitingPhase 4AstraZenecaNCT06651970Written as Acalabrutinib
- Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT04169737Written as Acalabrutinib
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingPhase 3Ascentage Pharma Group Inc.NCT06319456Written as Acalabrutinib
- Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell LymphomaRecruitingPhase 3Universität des SaarlandesNCT05820841Written as R-miniCHOP + Acalabrutinib
- Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07635511Written as Acalabrutinib maleate
- A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 3AbbVieNCT06428019Written as Acalabrutinib
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell LymphomaRecruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT05256641Written as Acalabrutinib
- Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasRecruitingPhase 2Emory UniversityNCT04883437Written as Acalabrutinib
- Avo In R/R And Previously Untreated MCLRecruitingPhase 1/2Austin I KimNCT04855695Written as Acalabrutinib
- Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLRecruitingPhase 2Zulfa OmerNCT07014917Written as Acalabrutinib
See all 123 studies that test acalabrutinib →
Given beside what is tested · 22 — acalabrutinib is usual care or a partner of the new treatment
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingPhase 2VA Office of Research and DevelopmentNCT06520098Written as Ibrutinib, Acalabrutinib, Zanubrutinib
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingPhase 1/2AstraZenecaNCT06564038Written as Acalabrutinib
- A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainRecruitingPhase 2AstraZenecaNCT07029737Written as Acalabrutinib combination with Rituximab
- A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLRecruitingPhase 1/2BioInvent International ABNCT03571568Written as Acalabrutinib
- A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLRecruitingPhase 3German CLL Study GroupNCT05197192Written as Acalabrutinib
- Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT07257055Written as Acalabrutinib
- Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic LeukemiaRecruitingPhase 2Ohio State University Comprehensive Cancer CenterNCT05336812Written as Acalabrutinib
- Mosunetuzumab for CLL MRD ClearanceRecruitingPhase 1/2Inhye AhnNCT07052695Written as Acalabrutinib
- A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Active, not recruitingPhase 1Acerta Pharma BVNCT03328273Written as Acalabrutinib
- Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCLActive, not recruitingPhase 2Weill Medical College of Cornell UniversityNCT03863184Written as Acalabrutinib
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingPhase 2Jennifer R. Brown, MD, PhDNCT04624633Written as Acalabrutinib
- Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLCompletedPhase 1Acerta Pharma BVNCT02296918Written as acalabrutinib
- Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell MalignanciesCompletedPhase 1/2Acerta Pharma BVNCT02328014Written as Acalabrutinib
- Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingPhase 1Acerta Pharma BVNCT02157324Written as acalabrutinib
- A Study Of The Selective PKC-β Inhibitor MS- 553TerminatedPhase 1/2MingSight Pharmaceuticals, IncNCT03492125Written as acalabrutinib
- AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood CancerCompletedPhase 1/2AstraZenecaNCT04630756Written as Acalabrutinib
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedPhase 2TG Therapeutics, Inc.NCT04016805Written as Acalabrutinib Oral Capsule
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedPhase 1Acerta Pharma BVNCT03527147Written as Acalabrutinib
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownPhase 1/2Kartos Therapeutics, Inc.NCT04502394Written as acalabrutinib
- A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult ParticipantsCompletedPhase 1Acerta Pharma BVNCT05140096Written as Acalabrutinib
Showing 20 of 22.
As the comparator · 4 — what is tested is compared with acalabrutinib
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136559Written as Acalabrutinib
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingPhase 3BeOne MedicinesNCT07277231Written as Acalabrutinib
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 3Guangzhou Lupeng Pharmaceutical Company LTD.NCT07377578Written as Acalabrutinib
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingPhase 3Loxo Oncology, Inc.NCT04662255Written as Acalabrutinib
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered2
- MACE and BTK InhibitorsNov 6, 2026NCT07923162
- Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialNov 2, 2026NCT07910435
Codes
What other systems call acalabrutinib · ClinicalTrials.gg INT000401
- MeSH (NLM) C000604908acalabrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) I42748ELQWACALABRUTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1986808Confirmed FDA, Wikidata
- Wikidata Q23668732acalabrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113442AcalabrutinibOne source FDA
- DrugBank DB11703One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604908 | acalabrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | I42748ELQW | ACALABRUTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1986808 | — | Confirmed FDA, Wikidata |
| Wikidata | Q23668732 | acalabrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113442 | Acalabrutinib | One source FDA |
| DrugBank | DB11703 | — | One source Wikidata |
Also registered as acalabrutinib maleate monohydrate (UNII 9GP2BPG9NS).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.